Your browser doesn't support javascript.
loading
Prognostic value of ctDNA detection in patients with early breast cancer undergoing neoadjuvant therapy: A systematic review and meta-analysis.
Papakonstantinou, Andri; Gonzalez, Nadia Saoudi; Pimentel, Isabel; Suñol, Anna; Zamora, Esther; Ortiz, Carolina; Espinosa-Bravo, Martin; Peg, Vicente; Vivancos, Ana; Saura, Cristina; Villacampa, Guillermo; Oliveira, Mafalda.
Afiliación
  • Papakonstantinou A; Breast Cancer Group, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain; Department of Oncology-Pathology, Karolinska Institute, Stockholm, Sweden; Department of Breast Cancer, Endocrine Tumors and Sarcoma, Karolinska University Hospital, Stockholm, Sweden.
  • Gonzalez NS; Breast Cancer Group, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain; Medical Oncology Department, Vall d'Hebron University Hospital, Barcelona, Spain.
  • Pimentel I; Breast Cancer Group, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain; Medical Oncology Department, Vall d'Hebron University Hospital, Barcelona, Spain.
  • Suñol A; Breast Cancer Group, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain.
  • Zamora E; Breast Cancer Group, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain; Medical Oncology Department, Vall d'Hebron University Hospital, Barcelona, Spain.
  • Ortiz C; Breast Cancer Group, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain; Medical Oncology Department, Vall d'Hebron University Hospital, Barcelona, Spain.
  • Espinosa-Bravo M; Breast Surgical Unit, Breast Cancer Center, Gynecology Department, Vall d'Hebron University Hospital, Universitat Autònoma de Barcelona, Spain.
  • Peg V; Department of Pathology, Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain; Universidad Autónoma de Barcelona, Barcelona, Spain; Spanish Biomedical Research Network Centre in Oncology (CIBERONC), Madrid, Spain.
  • Vivancos A; Cancer Genomics Lab, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain.
  • Saura C; Breast Cancer Group, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain; Medical Oncology Department, Vall d'Hebron University Hospital, Barcelona, Spain.
  • Villacampa G; Oncology Data Science Group, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain.
  • Oliveira M; Breast Cancer Group, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain; Medical Oncology Department, Vall d'Hebron University Hospital, Barcelona, Spain. Electronic address: moliveira@vhio.net.
Cancer Treat Rev ; 104: 102362, 2022 Mar.
Article en En | MEDLINE | ID: mdl-35219090
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias de la Mama / ADN Tumoral Circulante Tipo de estudio: Diagnostic_studies / Guideline / Observational_studies / Prognostic_studies / Risk_factors_studies / Systematic_reviews Límite: Female / Humans Idioma: En Revista: Cancer Treat Rev Año: 2022 Tipo del documento: Article País de afiliación: Suecia Pais de publicación: Países Bajos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias de la Mama / ADN Tumoral Circulante Tipo de estudio: Diagnostic_studies / Guideline / Observational_studies / Prognostic_studies / Risk_factors_studies / Systematic_reviews Límite: Female / Humans Idioma: En Revista: Cancer Treat Rev Año: 2022 Tipo del documento: Article País de afiliación: Suecia Pais de publicación: Países Bajos